Related Experiment Video
Updated: Jun 14, 2025
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.7K
Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis
Tamar Kvartskhava1, David Freudenstein1, Nicolas Sarmiento2
1Department of Neurology, University Hospital Regensburg, Regensburg, Germany.
Journal of the Neurological Sciences
|June 12, 2025
Summary
Ocrelizumab effectively reduces relapses and stabilizes disability in highly active relapsing-remitting multiple sclerosis (RRMS) when used as a first-line therapy. Early treatment initiation and lower baseline disability correlate with better outcomes in RRMS patients.
Area of Science:
- Neurology
- Immunology
- Clinical Therapeutics
Background:
- Early intervention with disease-modifying immunotherapies in relapsing-remitting multiple sclerosis (RRMS) shows promise in preventing disability.
- Ocrelizumab is a highly effective disease-modifying therapy for RRMS.
Purpose of the Study:
- To investigate the efficacy of ocrelizumab as a first-line therapy for patients with highly active RRMS.
- To evaluate the impact of early treatment initiation and baseline characteristics on treatment outcomes.
Main Methods:
- A retrospective, monocentric study of 33 RRMS patients receiving ocrelizumab as first-line therapy.
- Clinical evaluations every 6 months and annual MRI scans over a mean follow-up of 27 months.
- Subgroup analyses based on age, sex, disease duration, and EDSS at therapy initiation.
Main Results:
- Ocrelizumab significantly reduced the annualized relapse rate (ARR) from 2.24 to 0.058.
- Expanded Disability Status Scale (EDSS) remained stable throughout the follow-up period.
- Earlier treatment initiation and lower initial EDSS were associated with better outcomes; age and gender had no significant impact.
Conclusions:
- Ocrelizumab demonstrates significant efficacy as a first-line treatment for highly active RRMS.
- Early treatment with ocrelizumab is crucial for optimizing long-term outcomes in RRMS patients.
- Ocrelizumab is a valuable therapeutic option for managing highly active RRMS, with manageable infusion-related reactions and mild infections.
Keywords:
Disease modifying therapyFirst line therapyInduction therapyMultiple sclerosisOcrelizumabRelapsing-remitting multiple sclerosisMore Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
01:29Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
702
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
702